• Explore /
  • Poster
  • / Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03).

Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03).

Abstract Poster

Authors

Yelena Janjigian

Yelena Y. Janjigian

Memorial Sloan Kettering Cancer Center, New York, NY

Yelena Y. Janjigian , Saeed Raoufmoghaddam , Magdalena Sztachelska , Megan Winter , Satya (Nanu) Das

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04379596

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS424)

DOI

10.1200/JCO.2024.42.3_suppl.TPS424

Abstract #

TPS424

Poster Bd #

N9

Abstract Disclosures

Similar Posters

First Author: Yelena Y. Janjigian

First Author: Yelena Y. Janjigian

First Author: Yelena Y. Janjigian

First Author: Zhi Peng